Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site

Moscow, 119330, Russia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type 1 diabetes
Type 2 diabetes
Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion criteria

Unwilling to adhere to therapy or follow up
Pregnancy

Treatment and study plan

insulin detemir

Drug

Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.

Other names: Levemir®, NN304

Primary outcomes

HbA1C

Time frame: after 12 weeks

Secondary outcomes

Safety

Time frame: during treatment

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus

Acronym: PREDICTIVE™

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Apr 9, 2008
Registry last updated: Oct 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed